Overview

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate
Tofacitinib